Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Too many import alerts for Indian Pharma
Sep 24, 2013

As far as reputation goes, 2013 could probably be termed as the worst for the Indian pharma industry. Indeed, as the chart shows, around 19 import alerts were issued on plants of domestic pharma companies. When the US FDA issues an import alert on a particular plant, it means that drugs manufactured from that plant cannot be sold in the US unless certain corrective measures are put in place. The US generics market has always been an important and lucrative one for Indian Pharma because of the huge number of blockbuster drugs going off patent. Quite a few Indian companies had made increasing strides in the market. But given the Ranbaxy debacle and the fact that the US FDA has become stricter and more vigilant, Indian Pharma will have to get its act together. In an intensely competitive market such as the US, damage in reputation is bound to impact business in a big way.

Data Source: Business Standard

This Chart Of The Day was published in The 5 Minute WrapUp - India remains highly vulnerable to this event...

Equitymaster requests your view! Post a comment on "Too many import alerts for Indian Pharma". Click here!


Our Most Popular Charts

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms